188 related articles for article (PubMed ID: 37631251)
1. Formulation and Characterization of Ursodeoxycholic Acid Nanosuspension Based on Bottom-Up Technology and Box-Behnken Design Optimization.
Boscolo O; Flor S; Salvo L; Dobrecky C; Höcht C; Tripodi V; Moretton M; Lucangioli S
Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631251
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
3. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
4. Enhanced bioavailability of cinnarizine nanosuspensions by particle size engineering: Optimization and physicochemical investigations.
Mishra B; Sahoo J; Dixit PK
Mater Sci Eng C Mater Biol Appl; 2016 Jun; 63():62-9. PubMed ID: 27040196
[TBL] [Abstract][Full Text] [Related]
5. Study of Formulation and Process Variables for Optimization of Piroxicam Nanosuspension Using 3
Alhamhoom Y; Honmane SM; Hani U; Osmani RAM; Kandasamy G; Vasudevan R; Paramshetti S; R Dudhal R; K Kengar N; Charde MS
Polymers (Basel); 2023 Jan; 15(3):. PubMed ID: 36771784
[TBL] [Abstract][Full Text] [Related]
6. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability.
Parmar K; Shah J
Curr Drug Deliv; 2021; 18(8):1148-1161. PubMed ID: 33438540
[TBL] [Abstract][Full Text] [Related]
7. Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
Rahim H; Sadiq A; Khan S; Amin F; Ullah R; Shahat AA; Mahmood HM
Int J Nanomedicine; 2019; 14():6287-6296. PubMed ID: 31496686
[TBL] [Abstract][Full Text] [Related]
8. Formulation development and characterization of lumefantrine nanosuspension for enhanced antimalarial activity.
Shah R; Soni T; Shah U; Suhagia BN; Patel MN; Patel T; Gabr GA; Gorain B; Kesharwani P
J Biomater Sci Polym Ed; 2021 May; 32(7):833-857. PubMed ID: 33380264
[TBL] [Abstract][Full Text] [Related]
9. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach.
Chougule M; Sirvi A; Saini V; Kashyap M; Sangamwar AT
Drug Deliv Transl Res; 2023 Oct; 13(10):2503-2519. PubMed ID: 37024611
[TBL] [Abstract][Full Text] [Related]
10. Increase in Dissolution Rate of Zotepine via Nanomilling Process - Impact of Dried Nanocrystalline Suspensions on Bioavailability.
Parmar K; Oza K
AAPS PharmSciTech; 2021 Dec; 23(1):20. PubMed ID: 34907489
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization, and bioavailability of ursodeoxycholic acid-phospholipid complex in vivo.
Yue PF; Yuan HL; Xie H; Xiao XH; Yang M; Liao MX; Zhu WF; Cai PL
Drug Dev Ind Pharm; 2008 Jul; 34(7):708-18. PubMed ID: 18612911
[TBL] [Abstract][Full Text] [Related]
12. Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability.
Liu D; Xu H; Tian B; Yuan K; Pan H; Ma S; Yang X; Pan W
AAPS PharmSciTech; 2012 Mar; 13(1):295-304. PubMed ID: 22246736
[TBL] [Abstract][Full Text] [Related]
13. Exploring the Solvent-Anti-solvent Method of Nanosuspension for Enhanced Oral Bioavailability of Lovastatin.
Patil AS; Hegde R; Gadad AP; Dandagi PM; Masareddy R; Bolmal U
Turk J Pharm Sci; 2021 Oct; 18(5):541-549. PubMed ID: 34708645
[TBL] [Abstract][Full Text] [Related]
14. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.
Alshweiat A; Csóka I; Tömösi F; Janáky T; Kovács A; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Szabó-Révész P; Ambrus R
Int J Pharm; 2020 Apr; 579():119166. PubMed ID: 32084574
[TBL] [Abstract][Full Text] [Related]
15. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.
Wang Y; Wang S; Xu Y; Wang P; Li S; Liu L; Liu M; Jin X
Int J Nanomedicine; 2020; 15():7601-7613. PubMed ID: 33116490
[TBL] [Abstract][Full Text] [Related]
16. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation.
Freag MS; Elnaggar YS; Abdallah OY
Int J Pharm; 2013 Sep; 454(1):462-71. PubMed ID: 23830765
[TBL] [Abstract][Full Text] [Related]
17. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
Alsofany JM; Hamza MY; Abdelbary AA
AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766
[TBL] [Abstract][Full Text] [Related]
18. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.
Karakucuk A; Celebi N; Teksin ZS
Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836
[TBL] [Abstract][Full Text] [Related]
19. 24 Factorial Design Formulation Optimization and In vitro Characterization of Desloratadine Nanosuspension Prepared Using Antisolvent Precipitation.
El-Sebaiy MT; Alyami MH; Alyami HS; Kamal MA; Eissa N; Balata G; El-Nahas H
Curr Drug Deliv; 2024 Jun; ():. PubMed ID: 38867526
[TBL] [Abstract][Full Text] [Related]
20. Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability.
Thadkala K; Nanam PK; Rambabu B; Sailu C; Aukunuru J
Int J Pharm Investig; 2014 Jul; 4(3):131-7. PubMed ID: 25126526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
